NICE approves Cimzia but blocks Ilumetri in treatment of psoriasis
December 4, 2018Manufacturing and Production, Sales and Marketing Almirall, Cimzia, Ilumetri, NICE, UCB, UK, pharma, psoriasis
UK drug watchdog NICE has announced two new recommendations relating to medicines for the treatment of psoriasis, approving UCB Pharma’s …
Pfizer’s biosimilar proves non-inferior to rituximab in lymphoma at ASH 2018
December 4, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASH 2018, Pfizer, haemophilia
Joining the chorus of data presentations at the American Society of Hematology (ASH) Annual Meeting 2018, Pfizer has announced new …
Hemlibra shows “clinically meaningful” bleed control in paediatric haemophilia A patients
December 4, 2018Manufacturing and Production, Research and Development ASH 2018, Hemlibra, Roche, haemophilia, pharma
In another reveal at the American Society of Hematology (ASH) Annual Meeting 2018, Roche unveiled new Phase 3 findings for …
Cancer drug access for NHS patients is slowing, ICR reports
December 4, 2018Manufacturing and Production, Research and Development, Sales and Marketing Cancer, ICR, Institute of Cancer Research, NHS, NICE, UK, pharma
A new report from the Institute of Cancer Research (ICR) has indicated that NHS patients in the UK are suffering …
Roche chooses Veeva Vault PromoMats for digital asset management and content
December 4, 2018Manufacturing and Production, Medical Communications Roche, pharma, veeva
Today, at the 2018 Veeva Commercial & Medical Summit Europe, Roche (SWX:ROG) announced that it would be adopting Veeva Systems …
Insider Interview: The diabetes/mental health connection
December 3, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Insider Interview, Type 1 diabetes, World Diabetes Day, diabetes, feature, mental health, pharma
Michael Connellan, Head of External Affairs at the type 1 diabetes charity JDRF, discusses the results of a recent survey …
Shire’s Takhzyro scores EU approval in rare genetic disorder hereditary angioedema
December 3, 2018Sales and Marketing EU, Europe, Shire, Takhzyro, pharma
Shire has announced that it has secured European approval for its subcutaneous injection Takhzyro (lanadelumab) for the routine prevention of …
Gilead’s CAR-T therapy Yescarta shows two-year response duration in large B-cell lymphoma
December 3, 2018Research and Development, Sales and Marketing ASH 2-18, CAR-T, Cancer, Gilead, Yescarta, leukaemia, pharma
Gilead has gone head to head with Novartis at the American Society of Hematology (ASH) Annual Meeting 2018, meeting the …
GSK to acquire oncology biotech Tesaro for $5.1 billion
December 3, 2018Sales and Marketing GSK, GlaxoSmtihKline, Tesaro, acquisition, oncology, pharma
GlaxoSmithKline is set to acquire US-based oncology biotech Tesaro after both companies signed a definitive agreement with an aggregate cash …
AbbVie’s Venclyxto combo beats standard of care in chronic lymphocytic leukaemia
December 3, 2018Research and Development, Sales and Marketing ASH 2018, AbbVie, Cancer, Venclyxto, leukaemia, pharma
AbbVie has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to reveal new data on …
Novartis unveils strong longer-term Kymriah data at ASH 2018
December 3, 2018Research and Development, Sales and Marketing ASH 2018, Cancer, Kymriah, Novartis, leukaemia, pharma
Novartis has lifted the curtain on longer-term analysis data for its CAR-T therapy Kymriah (tisagenlecleucel) at the American Society of …
Top Ten most popular articles on Pharmafile.com this week
November 30, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, Immuno Biotech, NHS, Roche, autism, biosimilars, pharma, top ten
We’ve come to the end of November, and with only one month of the year left to go, the industry …
Opdivo to be made available to UK melanoma patients via the Cancer Drugs Fund
November 30, 2018Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, NICE, UK, melanoma, pharma
Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) is set to be made available to patients in the UK via the Cancer …
MSD chalks up two HIV drug approvals in Europe
November 30, 2018Medical Communications, Sales and Marketing Delstrigo, EU, Europe, HIV, MSD, Pifeltro, pharma
MSD has announced the European approval of two of its products for the treatment of HIV: the single-tablet combination Delstrigo …
83% in healthcare say UK will not be attractive for R&D and manufacturing post-Brexit
November 30, 2018Medical Communications, Research and Development R&D, UK, brexit, pharma
As the Brexit crisis continues to spiral, new findings from GlobalData reveal that 83% of healthcare professionals in the UK …
Bayer announces major restructure, 12,000 jobs to go
November 30, 2018Medical Communications, Sales and Marketing Bayer, job cuts, monsanto, pharma
Bayer has announced a major restructure of its operations in 2019 which will see the loss of 12,000 of its …
UK is among the first to meet UN targets for HIV treatment and prevention, Public Health England says
November 29, 2018Medical Communications HIV, UK, pharma
The UK is among the first countries in the world to meet the HIV treatment targets set out by the …
Astellas’ Xospata becomes US-approved drug for FLT3-mutated acute myeloid leukaemia
November 29, 2018Sales and Marketing Astellas, FDA, US, Xospata, acute myeloid leukamia
Astellas has revealed that Xospata (gilteritinib) has been awarded FDA approval as a treatment for relapsed or refractory acute myeloid …
FDA approves first Rituxan biosimilar courtesy of Teva and Celltrion
November 29, 2018Sales and Marketing FDA, Genentech, Rituxan, Roche, Teva, Truxima, biosimilars, celltrion
The FDA has announced the first US approval of a biosimilar version of Genentech’s Rituxan (rituximab), awarding marketing approval to …
Novartis’ Gilenya scores paediatric EU approval for advanced relapsing-remitting MS
November 29, 2018Sales and Marketing Europe, Novartis, UK, multiple sclerosis, pharma
Novartis has announced that Gilenya (fingolimod) has received marketing authorisation from the European Commission for the treatment of relapsing-remitting forms …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
